Scholarlink

<p>The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月12日

查看全文
  • Bertin C. Bisimwa,
  • Esto Bahizire,
  • Maja Kiselinova,
  • Valéry Byela,
  • Jean Claude S. Ngabonziza,
  • François Hakizayezu,
  • Docteur Runyambo,
  • Conor J. Meehan,
  • Wim Mulders,
  • Isabel Cuella-Martin,
  • Leen Rigouts,
  • Freddy Birembano,
  • Steven Callens,
  • Bouke C. de Jong,
  • Michel Kaswa

摘要

The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.